GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Other Stockholders Equity

Agenus (FRA:AJ8) Other Stockholders Equity : €0.0 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Other Stockholders Equity?

Agenus's Other Stockholders Equity for the quarter that ended in Mar. 2024 was €0.0 Mil.

Agenus's quarterly Other Stockholders Equity increased from Sep. 2023 (€-0.0 Mil) to Dec. 2023 (€-0.0 Mil) and increased from Dec. 2023 (€-0.0 Mil) to Mar. 2024 (€0.0 Mil).

Agenus's annual Other Stockholders Equity increased from Dec. 2021 (€-0.0 Mil) to Dec. 2022 (€0.0 Mil) but then declined from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€-0.0 Mil).


Agenus Other Stockholders Equity Historical Data

The historical data trend for Agenus's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Other Stockholders Equity Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agenus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Agenus Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Agenus Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Agenus's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (FRA:AJ8) Business Description

Industry
Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines